Fighting for victims of Trasylol
Email this page to a friend Print this page

WWW.FINZFIRM.COM
1-888-FINZFIRM
1-888-346-9347
Finz & Finz, P.C.
Attorneys And Counselors At Law

Bayer to stop sale of Trasylol

Nov 12, 2007 | Staff | Pittsburgh Business Times

Bayer AG said it would stop selling its bleeding treatment Trasylol after a study linked the product to a 50 percent higher risk of death than competing drugs in patients undergoing heart surgery.

The U.S. Food and Drug Administration asked the German drug giant to stop selling Trasylol, used to prevent excessive bleeding during heart-bypass surgery, until the agency could receive and review further results from the study.

Bayer has its U.S. headquarters in Robinson, near Pittsburgh, and employs about 1,500 in the region.

Meanwhile, the company said Tuesday that net income tripled to $1.71 billion, driven by a one-time tax benefit from the remeasurement of deferred tax liabilities, mostly due to the acquisition of Schering.


(required) Denotes required field


Title


(required) First Name


(required) Last Name


(required) Phone Number


Email Address


Address


City


(required) State


Zip Code


Best Way/Time to Contact You


Injured Person's Name


Injured Person's Date of Birth
(mm/dd/yyyy)

Date of Incident
(mm/dd/yyyy)

Type of Incident


Please Describe the Incident


Please sign me up for the Finz & Finz, P.C. Newsletter


I agree to the Finz & Finz, P.C. Terms of Use